Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer

被引：2
|
作者：
Torres, Alexandra
Kokkonen, Carey
Oladeji, Mary
D'Andrea, Kurt
Mick, Rosemarie
Narayan, Vivek
Mallamaci, Michael
Ewing, Gayle
Knollman, Hayley
Tung, Nadine M.
Robson, Mark
Nathanson, Katherine L.
Domchek, Susan
Shah, Payal D.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-18-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study
    Mayer, Erica L.
    DeMichele, Angela M.
    Guo, Hao
    Miller, Kathy D.
    Rugo, Hope S.
    Schneider, Bryan
    Waks, Adrienne G.
    Come, Steven E.
    Mulvey, Theresa
    Bartlett, Cynthia Huang
    Koehler, Maria
    Barry, William
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [42] Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience
    Battisti, N. M. L.
    Kingston, B.
    King, J.
    Denton, A.
    Waters, S.
    Sita-Lumsden, A.
    Rehman, F.
    Stavraka, C.
    Kristeleit, H.
    Sawyer, E.
    Houghton, D.
    Davidson, N.
    Howell, S.
    Choy, J.
    Harper, P.
    Roylance, R.
    Fharat, R.
    Mohammed, K.
    Ring, A.
    Johnston, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [44] A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
    Abusanad, Atlal
    Al Hashem, Hashem
    CASE REPORTS IN ONCOLOGY, 2021, 14 (01): : 446 - 452
  • [45] Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial
    Llombart-Cussac, Antonio
    Manuel Perez-Garcia, Jose
    Bellet, Meritxell
    Dalenc, Florence
    Gil-Gil, Miguel
    Ruiz-Borrego, Manuel
    Gavila, Joaquin
    Sampayo-Cordero, Miguel
    Aguirre, Elena
    Schmid, Peter
    Marme, Frederik
    Di Cosimo, Serena
    Gligorov, Joseph
    Schneeweiss, Andreas
    Albanell, Joan
    Zamora, Pilar
    Wheatley, Duncan
    Martinez-de Duenas, Eduardo
    Amillano, Kepa
    Malfettone, Andrea
    Cortes, Javier
    JAMA ONCOLOGY, 2021, 7 (12) : 1791 - 1799
  • [46] Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)
    Oliveira, Mafalda
    Bardia, Aditya
    Kim, Sung-Bae
    Niikura, Naoki
    Hernando, Cristina
    Werutsky, Gustavo
    Antill, Yoland
    Liedke, Pedro
    Oakman, Catherine
    Tokunaga, Eriko
    Wander, Seth
    Krause, Vanessa
    Yamashita, Toshinari
    Schimmoller, Frauke
    Rotmensch, Jacob
    Savage, Heidi
    Sane, Rucha
    Turner, Nicholas
    CANCER RESEARCH, 2022, 82 (04)
  • [47] PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
    Turner, Nicholas C.
    Ro, Jungsil
    Andre, Fabrice
    Loi, Sherene
    Verma, Sunil
    Iwata, Hiroji
    Harbeck, Nadia
    Loibl, Sibylle
    Bartlett, Cynthia Huang
    Zhang, Ke
    Giorgetti, Carla
    Randolph, Sophia
    Koehler, Maria
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [48] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [49] PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/ HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study
    Llombart-Cussac, Antonio
    Perez-Garcia, Jose Manuel
    Bellet-Ezquerra, Meritxell
    Dalenc, Florence
    Gil-Gil, Miguel
    Ruiz-Borrego, Manuel
    Gavila, Joaquin
    Schmid, Peter
    Zamora, Pilar
    Wheatley, Duncan
    Martinez-de Duenas, Eduardo
    Amillano, Kepa
    Anton, Antonio
    Cottu, Paul
    Vinas, Gemma
    Petit, Thierry
    Tesarova, Petra
    Cueva, Juan
    Colleoni, Marco
    del Prado, Maria Purificacion Martinez
    Andres, Raquel
    Cabo, Marta Diaz
    Victorino, Susana
    Sampayo-Cordero, Miguel
    Cortes, Javier
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Bingnan Zhang
    Elisa F. Long
    Breast Cancer Research and Treatment, 2019, 175 : 775 - 779
12345